Mediation of dopamine D2 receptors activation in post-conditioning-attenuated cardiomyocyte apoptosis

Exp Cell Res. 2014 Apr 15;323(1):118-130. doi: 10.1016/j.yexcr.2013.12.028. Epub 2014 Jan 9.

Abstract

The physiological and pathological roles of dopamine D2 receptors (DR2) in the regulation of cardiovacular functions have been recognized. DR2 activation protects hypoxia/reoxygenation (H/R)-induced cardiomyocyte injury and apoptosis, and ischemic post-conditioning (PC) plays a critical role in cardioprotection as well; however the involvement of the DR2 activation in the PC-induced cardioprotection is unknown. In the present study, we found that the H/R increased the expressions of DR2 mRNA and protein in cardiomyocytes, which were significantly enhanced by PC. Bromocriptine (Bro, a DR2 agonist) further increased DR2 expression, but Haloperidol (Hal, a DR2 antagonist) reversed the Bro-induced DR2 expressions. PC protected against H/R-induced apoptosis, the rise of [Ca(2+)]i, the expressions of cleaved caspase-3 and -9, release of cytochrome c, and mPTP opening. In addition, PC counteracted the reduction of cell viability caused by H/R, increased the phosphorylation of ERK1/2, PI3K, Akt, GSK-3β and mitochondrial membrane potential. PC further increased Bcl-2 expression, promoted PKC-ε translocation to cell membrane, and activated the mitochondrial ATP-sensitive K channels (mKATP). Bro further enhanced the cardioprotective roles of PC, but Hal reversed these effects of Bro. Meanwhile, we found that DR2 was expressed in cell membrane and interacted with PKC-ε in PC. In conclusion, these results suggest that PC attenuates cardiomyocyte apoptosis via inhibition of mPTP opening by DR2-mediated activation of ERK1/2, PI3K-Akt-GSK-3β and PKC-ε-mKATP. These findings provide a novel target for the treatment of ischemic cardiomyopathy.

Keywords: Cardiomyocytes; Dopamine D(2) receptors; Mitochondrial permeability transition pore; Post-conditioning.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Bromocriptine / pharmacology
  • Calcium / metabolism
  • Cardiotonic Agents
  • Caspase 3 / metabolism
  • Caspase 9 / metabolism
  • Cell Hypoxia
  • Cell Survival
  • Cytochromes c / metabolism
  • Dopamine Agonists / pharmacology
  • Dopamine Antagonists / pharmacology
  • Extracellular Signal-Regulated MAP Kinases / metabolism
  • Glycogen Synthase Kinase 3 / metabolism
  • Glycogen Synthase Kinase 3 beta
  • Haloperidol / pharmacology
  • Ischemic Postconditioning*
  • KATP Channels / metabolism
  • Membrane Potential, Mitochondrial / physiology
  • Mitochondrial Membrane Transport Proteins / metabolism
  • Mitochondrial Permeability Transition Pore
  • Myocardial Ischemia / drug therapy
  • Myocardial Ischemia / metabolism*
  • Myocytes, Cardiac / cytology
  • Myocytes, Cardiac / metabolism*
  • Phosphatidylinositol 3-Kinases / metabolism
  • Phosphorylation
  • Protein Kinase C-epsilon / metabolism
  • Protein Transport / physiology
  • Proto-Oncogene Proteins c-akt / metabolism
  • Proto-Oncogene Proteins c-bcl-2 / biosynthesis
  • RNA, Messenger / biosynthesis
  • Rats
  • Rats, Wistar
  • Receptors, Dopamine D2 / biosynthesis
  • Receptors, Dopamine D2 / genetics
  • Receptors, Dopamine D2 / metabolism*
  • Signal Transduction / drug effects
  • Signal Transduction / physiology

Substances

  • Cardiotonic Agents
  • Dopamine Agonists
  • Dopamine Antagonists
  • KATP Channels
  • Mitochondrial Membrane Transport Proteins
  • Mitochondrial Permeability Transition Pore
  • Proto-Oncogene Proteins c-bcl-2
  • RNA, Messenger
  • Receptors, Dopamine D2
  • Bromocriptine
  • Cytochromes c
  • Glycogen Synthase Kinase 3 beta
  • Gsk3b protein, rat
  • Proto-Oncogene Proteins c-akt
  • Protein Kinase C-epsilon
  • Extracellular Signal-Regulated MAP Kinases
  • Glycogen Synthase Kinase 3
  • Caspase 3
  • Caspase 9
  • Haloperidol
  • Calcium